A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

Sponsor
Eli Lilly and Company
Study ID
NCT02737072
Phase
PHASE1
Status
Terminated

Conditions

  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • LY2510924 — DRUG
    Administered SQ
  • Durvalumab — DRUG
    Administered IV

Study Details

The main purpose of this study is to evaluate the safety and tolerability of chemokine (C-X-C Motif) receptor 4 (CXCR4) peptide antagonist LY2510924 and durvalumab for phase 1a and 1b in participants with advanced refractory solid tumors.

Key Dates

Start date
Sep 30, 2016
Status verified
Jun 2019
Primary completion
Sep 25, 2017
Completion
Sep 25, 2017

Study Design

Enrollment
9 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 20 mg LY2510924 + 1500 mg Durvalumab
    20 milligrams (mg) LY2510924 given subcutaneously (SQ) once daily in combination with 1500 mg durvalumab given intravenously (IV) on Day 1 of each cycle (28 days).
  • Experimental: 30 mg LY2510924 + 1500 mg Durvalumab
    30 mg LY2510924 given SQ once daily in combination with 1500 mg durvalumab given IV on Day 1 of each cycle (28 days).
  • Experimental: 40 mg LY2510924 + 1500 mg Durvalumab
    40 mg LY2510924 given SQ once daily in combination with 1500 mg durvalumab given IV on Day 1 of each cycle (28 days).

Primary Outcome Measure

Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) [ Time Frame: Cycle 1 (28 Days) ]

Related Studies